Adlai Nortye Group (ANL) vs Annexon (ANNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Annexon (ANNX) over the past year, gaining 533.3% versus a loss of 27.4%. Annexon is the larger company by market cap ($591.4 million vs $550.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | ANNX |
|---|---|---|
| Share price | $8.55 | $3.10 |
| Market cap | $550.60M | $591.37M |
| 1-day change | -5.63% | -9.09% |
| YTD return | +502.11% | -38.25% |
| 1-year return | +533.33% | -27.40% |
| 5-year return | — | -77.37% |
| EPS (TTM) | $-0.66 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-51.87M | $-206.69M |
| 52-week high | $17.25 | $7.18 |
| 52-week low | $0.879 | $3.07 |
| Distance from 52-week high | -50.43% | -56.82% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +245.03% | +448.39% |
| Average volume | 244.74K | 3.36M |
| Shares outstanding | 58.73M | 190.76M |
| Employees | 109 | 97 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed ANNX by 560.7 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees
ANL vs ANNX FAQ
Which is bigger, Adlai Nortye Group or Annexon?
Annexon (ANNX) is larger, with a market capitalization of $591.37M compared with $550.60M for Adlai Nortye Group (ANL).
Which stock has performed better over the past year, ANL or ANNX?
ANL returned +533.33% over the past 12 months, compared with -27.40% for ANNX (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Annexon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.